Publication Name	World Journal of Virology
Manuscript ID	18645
Country	Japan

Received	2015-04-26 13:27
Peer-Review Started	2015-04-28 17:15
To Make the First Decision	2015-06-18 15:30
Return for Revision	2015-06-24 17:54
Revised	2015-06-25 09:12
Second Decision	2015-07-09 08:41
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-07-23 16:50
Articles in Press	2015-07-23 16:50
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-08-09 14:12
Publish the Manuscript Online	2015-08-13 10:30

ISSN	2220-3249 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?
Manuscript Source	Invited Manuscript
All Author List	Tatsuo Kanda, Shingo Nakamoto and Osamu Yokosuka
Funding Agency and Grant Number
Corresponding Author	Tatsuo Kanda, MD, PhD, Associate Professor, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. kandat-cib@umin.ac.jp
Key Words	Hepatitis C virus; Interleukin-28B; Interferon; Japan; Sustained virologic response
Core Tip	Genome-wide association studies have revealed that interleukin-28B (IL28B) genotypes are associated with the response to interferon therapy for chronic hepatitis C. The mechanism of this association is not yet clear. Although many hepatitis C virus (HCV)-infected individuals have IL28B favorable alleles, in the near future, HCV-infected patients in Japan may be treated with interferon-free regimens, which avoid the adverse events caused by interferon plus ribavirin therapy.
Publish Date	2015-08-13 10:30
Citation	Kanda T, Nakamoto S, Yokosuka O. Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C? World J Virol 2015; 4(3): 178-184
URL	http://www.wjgnet.com/2220-3249/full/v4/i3/178.htm
DOI	http://dx.doi.org/10.5501/wjv.v4.i3.178

Full Article (PDF)	WJV-4-178.pdf
Full Article (Word)	WJV-4-178.doc
Manuscript File	18645-Review.doc
Answering Reviewers	18645-Answering reviewers.pdf
Audio Core Tip	18645-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	18645-Conflict-of-interest statement.pdf
Copyright License Agreement	18645-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	18645-Language certificate.pdf
Peer-review Report	18645-Peer-review(s).pdf
Scientific Misconduct Check	18645-Scientific misconduct check.pdf
Scientific Editor Work List	18645-Scientific editor work list.pdf